Obesity (Disorder)MNEMOBNCT07796932
Characterisation of MNEsic Involvement in Patients With Obesity.
An observational study of Obesity (Disorder), run by University Hospital, Bordeaux.
Trial summary
The aim of the study is therefore to characterise memory impairment in a middle-aged population with obesity and to clarify the role of inflammation in obesity-related memory impairment. Read more about this study
- Who is it for?
- Ages 30 to 50 years
- Conditions the study is for
- Obesity (Disorder)
- What is being tested?
- RMI and Questionnaires
- How many people
- 150 participants
- Where
- No sites listed yet
- Study dates
- Jan 2027to Feb 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 50 years
- All sexes
- No healthy volunteers
- Adult
Study population: Recruitment will take place within the Specialised Obesity Centre at Bordeaux University Hospital. As part of their obesity treatment within the department, new patients first attend a consultation, after which they are usually admitted for a five-day educational programme to undergo a comprehensive initial multidisciplinary assessment (covering medical, dietary, psychological, physical activity and social aspects).
Who may be able to join
- Patients suffering from obesity with a BMI between 30 and 45 kg/m²
- Patients aged between 30 and 50 receiving educational care during the week at the CSO (Endocrinology, Diabetology and Nutrition Department) of the Bordeaux University Hospital.
- Right-handed patients
- Persons affiliated with or beneficiaries of a social security scheme.
- Free, informed and express consent
Who cannot join
- Patients currently undergoing treatment with neuroleptics or who have stopped treatment within the last 3 months.
- Pregnant or breastfeeding patients
- Known current or past neurological disease
- Proven depressive syndrome treated
- Patients with type 1 or type 2 diabetes
- Uncontrolled dysthyroidism
Show all 14Show fewer
- MMS< 25
- Patients with proven genetic obesity
- Contraindication to MRI
- Chronic use of NSAIDs or corticosteroids
- Loss of 5% of body weight in the 3 months prior to the study
- Acute infection
- Persons deprived of their liberty by judicial or administrative decision
- Adults subject to legal protection measures (guardianship, curatorship, judicial protection)
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The aim of the study is therefore to characterise memory impairment in a middle-aged population with obesity and to clarify the role of inflammation in obesity-related memory impairment.
The hypothesise that, as in an elderly population, neurological and memory impairment in a population of middle-aged obese individuals is heterogeneous, with varying levels of memory impairment characterised by neuropsychological test results. This heterogeneity in neuropsychological tests may be linked to markers of inflammation and brain imaging biomarkers identified previously in the litterature.
- Conditions
- Obesity (Disorder)
- Being tested
- RMI and Questionnaires
- Keywords
- neurological inflammation, Obesity, CANTAB
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RMI and QuestionnairesOther
Magnetic resonance imaging (MRI) will collect anatomical information (3D T1 weighted images) to compute the volumes of the hypothalamus, hippocampus and the other brain parcels.
Executive functions using the CANTAB tests and validated questionnaires will be performed.
| Study group | Role | What they receive |
|---|---|---|
| Magnetic Resonance Imaging, CANTAB questionnaires | Not described Receives: Other: RMI and Questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Memory function characteristic
The main objective is to characterise memory function in a population of middle-aged individuals suffering from obesity using the CANTAB Paired Associates Learning (PAL) test.
Measured: 37 months after inclusion day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2026
- Study startJan 2027 (estimated)
- Primary completionFeb 2030 (estimated)
- Study completionFeb 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity (Disorder)Studies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Daniela COTA, Pr, Study director, INSERM u1215
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07796932
- Sponsor's protocol ID
- CHUBX 2025/068
- Acronym
- MNEMOB
- Status last verified
- Aug 2026
- First submitted
- 22 Jul 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterisation of MNEsic Involvement in Patients With Obesity.
- ClinicalTrials.gov ID
- NCT07796932
- Acronym / sponsor ID
- MNEMOB / CHUBX 2025/068
- Conditions
- Obesity (Disorder)
- Keywords
- neurological inflammation, Obesity, CANTAB
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- Jan 2027 (estimated)
- Primary completion
- Feb 2030 (estimated)
- Study completion
- Feb 2030 (estimated)
- First posted
- 1 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is therefore to characterise memory impairment in a middle-aged population with obesity and to clarify the role of inflammation in obesity-related memory impairment.
The hypothesise that, as in an elderly population, neurological and memory impairment in a population of middle-aged obese individuals is heterogeneous, with varying levels of memory impairment characterised by neuropsychological test results. This heterogeneity in neuropsychological tests may be linked to markers of inflammation and brain imaging biomarkers identified previously in the litterature.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Magnetic Resonance Imaging, CANTAB questionnaires | – | Other: RMI and Questionnaires |
Who may qualify
- Ages
- 30 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Recruitment will take place within the Specialised Obesity Centre at Bordeaux University Hospital. As part of their obesity treatment within the department, new patients first attend a consultation, after which they are usually admitted for a five-day educational programme to undergo a comprehensive initial multidisciplinary assessment (covering medical, dietary, psychological, physical activity and social aspects).
Key inclusion criteria (5 listed)
- Patients suffering from obesity with a BMI between 30 and 45 kg/m²
- Patients aged between 30 and 50 receiving educational care during the week at the CSO (Endocrinology, Diabetology and Nutrition Department) of the Bordeaux University Hospital.
- Right-handed patients
- Persons affiliated with or beneficiaries of a social security scheme.
- Free, informed and express consent
Key exclusion criteria (14 listed)
- Patients currently undergoing treatment with neuroleptics or who have stopped treatment within the last 3 months.
- Pregnant or breastfeeding patients
- Known current or past neurological disease
- Proven depressive syndrome treated
- Patients with type 1 or type 2 diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RMI and QuestionnairesMagnetic resonance imaging (MRI) will collect anatomical information (3D T1 weighted images) to compute the volumes of the hypothalamus, hippocampus and the other brain parcels. Executive functions using the CANTAB tests and validated questionnaires will be performed. | Other | Magnetic Resonance Imaging, CANTAB questionnaires |
Primary outcome
Memory function characteristic
Time frame: 37 months after inclusion day
The main objective is to characterise memory function in a population of middle-aged individuals suffering from obesity using the CANTAB Paired Associates Learning (PAL) test.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity (Disorder)
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Daniela COTA, Pr study director
INSERM u1215
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity (Disorder), run by University Hospital, Bordeaux.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Blandine GATTA-CHERIFI, Pr (05 24 54 93 41 ext. +33, blandine.gatta-cherifi@chu-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Memory function characteristic (time frame: 37 months after inclusion day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.